LadRx Announces Receipt of $75 Million Milestone Payment from ImmunityBio
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced today that it has received $75 million payment under the license agreement with ImmunityBio.